Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Incyte Corporation

NASDAQ

Market Cap.

12.89B

Avg. Volume

2.04M

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Incyte Corporation!

Still processing it, give me a bit more time...

Incyte Corporation News

Incyte Corporation Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Website screenshot
HealthcareBiotechnology
incyte.com

About Incyte Corporation

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Incyte Corporation Earnings & Revenue

Incyte Corporation Financials

Table Compare

Compare INCY metrics with:

   

Earnings & Growth

INCY

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

INCY

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

INCY

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

INCY

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Incyte Corporation Income

Incyte Corporation Balance Sheet

Incyte Corporation Cash Flow

Incyte Corporation Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityBuy
Return on AssetsStrong Buy
Debt/Equity RatioSell
Price/Earnings RatioBuy
Price/Book RatioNeutral

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Incyte Corporation Executives

NameRole
Mr. Herve HoppenotChief Executive Officer & Chairman
Dr. Pablo J. Cagnoni M.D., Ph.D.President and Head of Research & Development
Dr. Steven H. Stein M.D.Executive Vice President & Chief Medical Officer
Ms. Christiana Stamoulis MBAExecutive Vice President & Chief Financial Officer
Dr. Barry P. Flannelly M.B.A., Pharm.D.Executive Vice President & GM of North America
NameRoleGenderDate of BirthPay
Mr. Herve HoppenotChief Executive Officer & ChairmanMale19602.9M
Dr. Pablo J. Cagnoni M.D., Ph.D.President and Head of Research & Development19632.03M
Dr. Steven H. Stein M.D.Executive Vice President & Chief Medical Officer19671.32M
Ms. Christiana Stamoulis MBAExecutive Vice President & Chief Financial OfficerFemale19711.18M
Dr. Barry P. Flannelly M.B.A., Pharm.D.Executive Vice President & GM of North America19581.01M

Incyte Corporation Insider Trades

Date7 May
NameBAKER BROS. ADVISORS LP
RoleDirector, 10 percent owner
TransactionAcquired
TypeM-Exempt
Shares15000
Date7 May
NameBAKER BROS. ADVISORS LP
RoleDirector, 10 percent owner
TransactionAcquired
TypeM-Exempt
Shares15000
Date7 May
NameBAKER BROS. ADVISORS LP
RoleDirector, 10 percent owner
TransactionDisposed
TypeM-Exempt
Shares15000
Date28 Mar
NameClancy Paul J
RoleDirector
TransactionAcquired
TypeA-Award
Shares403
Date28 Mar
NameHARRIGAN EDMUND
RoleDirector
TransactionAcquired
TypeA-Award
Shares413
DateNameRoleTransactionTypeShares
7 MayBAKER BROS. ADVISORS LPDirector, 10 percent ownerAcquiredM-Exempt15000
7 MayBAKER BROS. ADVISORS LPDirector, 10 percent ownerAcquiredM-Exempt15000
7 MayBAKER BROS. ADVISORS LPDirector, 10 percent ownerDisposedM-Exempt15000
28 MarClancy Paul JDirectorAcquiredA-Award403
28 MarHARRIGAN EDMUNDDirectorAcquiredA-Award413

Discover More

Streamlined Academy

Incyte Corporation

NASDAQ

Market Cap.

12.89B

Avg. Volume

2.04M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Incyte Corporation News

Incyte Corporation Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Incyte Corporation Earnings & Revenue

Incyte Corporation Income

Incyte Corporation Balance Sheet

Incyte Corporation Cash Flow

Incyte Corporation Financials Over Time

Incyte Corporation Executives

NameRole
Mr. Herve HoppenotChief Executive Officer & Chairman
Dr. Pablo J. Cagnoni M.D., Ph.D.President and Head of Research & Development
Dr. Steven H. Stein M.D.Executive Vice President & Chief Medical Officer
Ms. Christiana Stamoulis MBAExecutive Vice President & Chief Financial Officer
Dr. Barry P. Flannelly M.B.A., Pharm.D.Executive Vice President & GM of North America
NameRoleGenderDate of BirthPay
Mr. Herve HoppenotChief Executive Officer & ChairmanMale19602.9M
Dr. Pablo J. Cagnoni M.D., Ph.D.President and Head of Research & Development19632.03M
Dr. Steven H. Stein M.D.Executive Vice President & Chief Medical Officer19671.32M
Ms. Christiana Stamoulis MBAExecutive Vice President & Chief Financial OfficerFemale19711.18M
Dr. Barry P. Flannelly M.B.A., Pharm.D.Executive Vice President & GM of North America19581.01M

Incyte Corporation Insider Trades

Date7 May
NameBAKER BROS. ADVISORS LP
RoleDirector, 10 percent owner
TransactionAcquired
TypeM-Exempt
Shares15000
Date7 May
NameBAKER BROS. ADVISORS LP
RoleDirector, 10 percent owner
TransactionAcquired
TypeM-Exempt
Shares15000
Date7 May
NameBAKER BROS. ADVISORS LP
RoleDirector, 10 percent owner
TransactionDisposed
TypeM-Exempt
Shares15000
Date28 Mar
NameClancy Paul J
RoleDirector
TransactionAcquired
TypeA-Award
Shares403
Date28 Mar
NameHARRIGAN EDMUND
RoleDirector
TransactionAcquired
TypeA-Award
Shares413
DateNameRoleTransactionTypeShares
7 MayBAKER BROS. ADVISORS LPDirector, 10 percent ownerAcquiredM-Exempt15000
7 MayBAKER BROS. ADVISORS LPDirector, 10 percent ownerAcquiredM-Exempt15000
7 MayBAKER BROS. ADVISORS LPDirector, 10 percent ownerDisposedM-Exempt15000
28 MarClancy Paul JDirectorAcquiredA-Award403
28 MarHARRIGAN EDMUNDDirectorAcquiredA-Award413

Streamlined Academy

Website screenshot
HealthcareBiotechnology
incyte.com

About Incyte Corporation

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Incyte Corporation!

Still processing it, give me a bit more time...

Incyte Corporation Financials

Table Compare

Compare INCY metrics with:

   

Earnings & Growth

INCY

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

INCY

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

INCY

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

INCY

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Incyte Corporation Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityBuy
Return on AssetsStrong Buy
Debt/Equity RatioSell
Price/Earnings RatioBuy
Price/Book RatioNeutral

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More